share_log

Canopy Growth | 10-Q: Q1 2025 Earnings Report

Canopy Growth | 10-Q: Q1 2025 Earnings Report

Canopy Growth | 10-Q：2025財年一季報
美股SEC公告 ·  2024/08/09 18:32

Moomoo AI 已提取核心訊息

Canopy Growth Corporation reported Q1 fiscal 2025 financial results with net revenue declining 13% year-over-year to $66.2 million, while gross margin improved to 35% from 18%. The company recorded a net loss from continuing operations of $129.2 million, compared to a $10.6 million loss in Q1 fiscal 2024. The increased loss was primarily driven by non-cash fair value changes in financial instruments.The Canada cannabis segment revenue decreased 6% to $37.7 million, with adult-use cannabis down 22% to $18.9 million due to supply constraints and price competition. However, medical cannabis revenue grew 20% to $18.8 million. International markets cannabis revenue remained stable at $10.1 million, while Storz & Bickel revenue increased 2% to $18.5 million.The company strengthened its balance sheet through several initiatives including exchanging $81.2 million of promissory notes into exchangeable shares, raising $68.3 million through a convertible debenture offering, and establishing a $250 million ATM program. Canopy Growth also completed the deconsolidation of Canopy USA as of April 30, 2024 and extended its credit facility maturity to December 2026.
Canopy Growth Corporation reported Q1 fiscal 2025 financial results with net revenue declining 13% year-over-year to $66.2 million, while gross margin improved to 35% from 18%. The company recorded a net loss from continuing operations of $129.2 million, compared to a $10.6 million loss in Q1 fiscal 2024. The increased loss was primarily driven by non-cash fair value changes in financial instruments.The Canada cannabis segment revenue decreased 6% to $37.7 million, with adult-use cannabis down 22% to $18.9 million due to supply constraints and price competition. However, medical cannabis revenue grew 20% to $18.8 million. International markets cannabis revenue remained stable at $10.1 million, while Storz & Bickel revenue increased 2% to $18.5 million.The company strengthened its balance sheet through several initiatives including exchanging $81.2 million of promissory notes into exchangeable shares, raising $68.3 million through a convertible debenture offering, and establishing a $250 million ATM program. Canopy Growth also completed the deconsolidation of Canopy USA as of April 30, 2024 and extended its credit facility maturity to December 2026.
Canopy Growth公司報告了2025財年第一季度的財務結果，淨營業收入同比下降13%，降至6620萬，而毛利率從18%提高到35%。公司記錄的持續運營淨虧損爲12920萬，而2024財年第一季度的虧損爲1060萬。這一虧損的增加主要是由於金融工具公允價值的非現金變動所致。加拿大大麻業務的營業收入下降6%，降至3770萬，成人用大麻下降22%，降至1890萬，主要由於供應限制和價格競爭。然而，醫療大麻的營業收入增長了20%，達到1880萬。國際市場的大麻收入保持穩定，達到了1010萬，而Storz & Bickel的營業收入增長了2%，達到1850萬。公司通過多項舉措增強了其資產負債表，包括將8120萬的票據轉換爲可交換股票，通過可轉換債券發行籌集6830萬，以及建立25000萬的ATm項目。Canopy Growth還在2024年4月30日完成了Canopy USA的去整合，並將信用設施的到期日延長至2026年12月。
Canopy Growth公司報告了2025財年第一季度的財務結果，淨營業收入同比下降13%，降至6620萬，而毛利率從18%提高到35%。公司記錄的持續運營淨虧損爲12920萬，而2024財年第一季度的虧損爲1060萬。這一虧損的增加主要是由於金融工具公允價值的非現金變動所致。加拿大大麻業務的營業收入下降6%，降至3770萬，成人用大麻下降22%，降至1890萬，主要由於供應限制和價格競爭。然而，醫療大麻的營業收入增長了20%，達到1880萬。國際市場的大麻收入保持穩定，達到了1010萬，而Storz & Bickel的營業收入增長了2%，達到1850萬。公司通過多項舉措增強了其資產負債表，包括將8120萬的票據轉換爲可交換股票，通過可轉換債券發行籌集6830萬，以及建立25000萬的ATm項目。Canopy Growth還在2024年4月30日完成了Canopy USA的去整合，並將信用設施的到期日延長至2026年12月。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    坎伯蘭藥業
    CPIX
    -- 4.410
    IM Cannabis
    IMCC
    -- 1.839
    Journey Medical
    DERM
    -- 6.110
    Quantum BioPharma
    QNTM
    -- 8.560
    Citius Oncology
    CTOR
    -- 0.665
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股財報季火熱：驚喜盈利能否延續漲勢？
    1. 哪些行業可能成為本輪財報季的市場焦點？ 2. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？ 展开
    中國兩會：會議前後股票價格變動的關鍵要點